Home
Olema Oncology

Olema Oncology Market Share Analysis for August 2026

Explore career opportunities at Olema Oncology and join a collaborative biotech team focused on advancing therapies for patients with breast cancer.

Health > Biotechnology and Pharmaceuticals

Domainolema.com

Year Founded2007

Employees51 - 200

Annual Revenue--

Olema Oncology

Olema Oncology (including company regionals)

olema.com

See more website traffic and engagement information

Total visits to Olema Oncology's top domains

Understand Olema Oncology market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

olema.com5.7K

See more with Sales Intelligence

Avg. visit duration in Olema Oncology's top domains

Analyze Olema Oncology engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

olema.com00:00:36

See more with Sales Intelligence

Avg. pageviews on Olema Oncology's top domains

See how Olema Oncology keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

olema.com2.08

See more with Sales Intelligence

Olema Oncology top competitors by domain

Top similar sites in August 2026, ranked by their affinity

kuraoncology.comCompany NameKura OncologyEmployees51 - 200HQUnited States, California, San DiegoAnnual revenue$25M - $50MTotal visits21.2KHealth > Biotechnology and Pharmaceuticals

Top technologies used by Olema Oncology

These are the website technologies, by industry, used by Olema Oncology top domains

Advertising (5)

DoubleClick

Conversion & Analytics (3)

Google Analytics

Audio Video Media (2)

YouTube

Content Management System (2)

WordPress

More Technologies

12

See all

News & Signals from Olema Oncology

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsOlema Pharmaceuticals, Inc. is developing palazestrant on Sep 2nd '26.* Olema's ongoing commitment to developing innovative therapies for breast cancer, including their lead product candidate, palazestrant, underlines the company's focus on advancing significant medical solutions.

NewsOlema Pharmaceuticals, Inc. hired Jason V. O'Byrne as Chief Financial Officer on Aug 11th '26.SAN FRANCISCO, Sept. 02, 2026 (GLOBE NEWSWIRE) - Olema Pharmaceuticals, Inc. ("Olema" or "Olema Oncology", Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that, in connection with the appointment of Jason V. O'Byrne as Chief Financial Officer effective August 11, 2026, the Company granted Mr. O'Byrne an employment inducement award consisting of stock options to purchase 650,000 shares of the Company's common stock, with an effective grant date of September 1, 2026 and an exercise price of $10.56 per share, equal to the last reported sale price of the Company's common stock as reported by Nasdaq on September 1, 2026.

NewsOlema Pharmaceuticals, Inc. is developing OP-3136 on May 26th '26.In addition, Olema is developing OP-3136, a potent lysine acetyltransferase 6 (KAT6) inhibitor, now in a Phase 1 clinical study.